Finsterer, J. (2020). Rhabdomyolysis, renal failure, and visual loss under BRAF/MEK inhibitors trametinib and dabrafenib. Revista Médica De Chile, 148(11). Recuperado a partir de https://revistamedicadechile.cl/index.php/rmedica/article/view/7796